# Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Source: https://onco.cc/trials/nct05988372/  
OnCo record `nct05988372` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of surufatinib, serplulimab and gemcitabine in pancreatic cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) is a phase 2, randomised interventional study registered as NCT05988372 by Sun Yat-sen University, with a registry enrolment figure of 50 participants, started 2023-10-23 and due to reach its primary completion in 2023-10-23. Interventions recorded: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine; Albumin-paclitaxel + Gemcitabine. Conditions listed: Locally Advanced Pancreatic Cancer. Primary outcome: R0 Surgical Resection Rate. Pancreatic eligibility wording from the registry: "Pathologically confirmed unresectable locally advanced pancreatic cancer, received no surgical therapy". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05988372
- Phase: 2
- Setting: Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer : a Phase II Randomized Controlled PILOT Study (SAGE)
- Sponsor: Sun Yat-sen University
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT05988372: https://clinicaltrials.gov/study/NCT05988372

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Serplulimab](https://onco.cc/drugs/serplulimab/), [Surufatinib](https://onco.cc/drugs/surufatinib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05988372.json